Intra-Cellular Therapies Inc., of New York, said results published in Biological Psychiatry from a phase II trial of ITI-007 in patients with schizophrenia showed the drug significantly improved symptoms in patients experiencing an acute exacerbation of schizophrenia at a dose of 60 mg daily, as demonstrated by a statistically significant separation from placebo on the Positive and Negative Syndrome Scale (PANSS) total score at four weeks, the primary endpoint.